Bladder Cancer is the fourth most common cancer among men in Europe and the U.S. With up to 80% recurrence, bladder cancer requires lifelong surveillance, making it one of the most expensive cancers in terms of lifetime cost per patient. In this context, there is a real need for non-invasive, accurate, simple and cost effective diagnostic solutions.
CellDetect Bladder is an innovative urinary marker for the early detection of bladder cancer in urine specimens. Combining color and morphology, CellDetect is particularly useful for the detection of low grade tumors. It was also shown to predate bladder cancer relapse, making it an effective early indicator of recurrence.
CellDetect Bladder is also approved for use in Europe, Israel and other territories.